Cargando…
Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations
Pulmonary exacerbations are common events in cystic fibrosis and have a profound impact on quality of life, morbidity, and mortality. Pulmonary exacerbation outcomes remain poor and a significant proportion of patients fail to recover their baseline lung function despite receiving aggressive treatme...
Autores principales: | Skolnik, Kate, Quon, Bradley S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954331/ https://www.ncbi.nlm.nih.gov/pubmed/29862015 http://dx.doi.org/10.12688/f1000research.13926.1 |
Ejemplares similares
-
Nontuberculous Mycobacteria in Cystic Fibrosis
por: Skolnik, Kate, et al.
Publicado: (2016) -
Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations
por: Sharma, Ashutosh, et al.
Publicado: (2017) -
Metabolomic Biomarkers to Predict and Diagnose Cystic Fibrosis Pulmonary Exacerbations: A Systematic Review
por: Nguyen, Anna-Lisa V., et al.
Publicado: (2022) -
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
por: Habib, Al-Rahim R., et al.
Publicado: (2019) -
Plasma sCD14 as a Biomarker to Predict Pulmonary Exacerbations in Cystic Fibrosis
por: Quon, Bradley S., et al.
Publicado: (2014)